Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v3.22.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Revenue $ 3,130 $ 10,000 $ 7,826 $ 10,000
Operating expense:        
Cost of revenues 17,430 10,102 34,223 10,102
Selling, general and administrative expense 1,208,910 1,339,833 2,472,013 2,230,024
Research and development expense 527,656 410,611 762,274 754,202
Total costs and expenses 1,753,996 1,760,546 3,268,510 2,994,328
Loss from operations (1,750,866) (1,750,546) (3,260,684) (2,984,328)
Other income (expense):        
Interest expense (39,452) (40,750) (79,781) (70,016)
Decrease to fair value of derivative liability 1,000,000 0 1,000,000 108,944
Total other income (expense) 960,548 (40,750) 920,219 38,928
Net loss $ (790,318) $ (1,791,296) $ (2,340,465) $ (2,945,400)
Loss per share - basic and diluted        
Net loss per common share - basic and diluted (in dollars per share) $ 0.00 $ (0.01) $ (0.01) $ (0.01)
Weighted common shares - basic and diluted (in shares) 236,865,603 213,337,625 236,806,034 203,135,751